TY - JOUR
T1 - Dendritic cells, inflammation, and breast cancer
AU - Palucka, Karolina
AU - Coussens, Lisa M.
AU - O'Shaughnessy, Joyce
PY - 2013/11
Y1 - 2013/11
N2 - Solid tumors are well known for their genomic heterogeneity. Although some aspects of this derive from so-called driver mutations, it is now clear that tumor cells possess a seemingly limitless capacity to evade cell death pathway activation, maintain essential survival programming, and initiate resistance networks that block efficacy of cytotoxic and targeted therapy. Given this amazing survival capability, how then to design approaches for effective eradication of malignant cells Also present within all solid tumors is a diverse assemblage of genomically stable immune cell types. Whereas some of these possess documented activities that foster tumor progression, others possess inherent activities that when favored lead to rapid tumor cell elimination. This review focuses on aspects of dendritic cell biology in solid tumors, especially breast cancers, which point to dendritic cells as a tractable tool to exploit for immune-based therapies.
AB - Solid tumors are well known for their genomic heterogeneity. Although some aspects of this derive from so-called driver mutations, it is now clear that tumor cells possess a seemingly limitless capacity to evade cell death pathway activation, maintain essential survival programming, and initiate resistance networks that block efficacy of cytotoxic and targeted therapy. Given this amazing survival capability, how then to design approaches for effective eradication of malignant cells Also present within all solid tumors is a diverse assemblage of genomically stable immune cell types. Whereas some of these possess documented activities that foster tumor progression, others possess inherent activities that when favored lead to rapid tumor cell elimination. This review focuses on aspects of dendritic cell biology in solid tumors, especially breast cancers, which point to dendritic cells as a tractable tool to exploit for immune-based therapies.
KW - Cancer
KW - Dendritic Cells
KW - Immunogenic Cell Death
KW - Inflammation
KW - h
UR - http://www.scopus.com/inward/record.url?scp=84889048897&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84889048897&partnerID=8YFLogxK
U2 - 10.1097/PPO.0000000000000007
DO - 10.1097/PPO.0000000000000007
M3 - Review article
C2 - 24270350
AN - SCOPUS:84889048897
SN - 1528-9117
VL - 19
SP - 511
EP - 516
JO - Cancer Journal (United States)
JF - Cancer Journal (United States)
IS - 6
ER -